logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASH 2018 — Add-on daratumumab boosts PFS in transplant-ineligible MM

Phase 3 MAIA study supports daratumumab plus Rd as the new standard of care.